Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "Longevity Market Report 2026-2036" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue for Longevity Market will surpass US$740 billion in 2026
This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The longevity market is undergoing a structural shift, moving beyond predominantly consumer-driven wellness offerings toward institutionally funded healthcare solutions. Insurers, employers, health systems and pharmaceutical companies are increasingly integrating longevity-focused strategies to address the challenges of ageing populations, rising chronic disease burden and long-term cost sustainability. This evolution is accelerating demand for integrated platforms that enable early risk identification, targeted prevention and ongoing clinical engagement across the life course.
This report assesses the factors underpinning longevity's transition into an investable market at scale. It examines how longitudinal health data and digital infrastructure are emerging as durable competitive assets, how reimbursement and regulatory frameworks are influencing market structure, and how pharmaceutical and payer participation is redefining the scope of the longevity ecosystem. The analysis is intended to support strategic planning, investment evaluation and market-entry decisions through to 2036.
Advances in AI, Genomics and Regenerative Medicine Are Accelerating Longevity Market Development
Advances in artificial intelligence, genomics and regenerative medicine are increasingly shaping the development trajectory of the global longevity market by improving discovery efficiency, clinical precision and translational feasibility. AI-enabled platforms are being used to analyse multi-omics and longitudinal datasets, supporting faster identification of drug targets linked to recognised biological processes associated with ageing, including metabolic dysregulation, cellular senescence and immune dysfunction. These capabilities are shortening early-stage discovery timelines and improving candidate prioritisation rather than replacing traditional development pathways.
In genomics, progress in gene-editing technologies and biomarker profiling is enabling more targeted interventions for age-related diseases, supporting personalised treatment strategies while maintaining strict regulatory oversight. A notable regulatory milestone occurred on 27th September 2024, when Health Canada approved Casgevy (exa-cel), the CRISPR-based gene therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease and transfusion-dependent beta-thalassaemia. While not an anti-ageing therapy, the approval reinforces regulatory willingness to support high-complexity genetic medicines relevant to conditions that disproportionately affect ageing populations.
At the same time, regenerative medicine programmes continue to advance cellular and tissue-repair approaches, including investigational epigenetic and gene-therapy platforms aimed at improving resilience across metabolic, cardiovascular, musculoskeletal and neurological systems. Collectively, these technological advances are strengthening the scientific and regulatory foundations of the longevity market, enabling gradual transition from research-driven innovation toward clinically validated, scalable interventions.
Digital Health, Remote Monitoring and Longevity Clinics Are Reinforcing Market Adoption
Digital health platforms, remote monitoring technologies and longevity clinics are strengthening the global longevity market by enabling proactive, data-driven healthspan management rather than episodic care. Wearables that track sleep, physical activity and heart rate variability (HRV) support continuous risk assessment and early identification of ageing-related decline, allowing timely lifestyle and clinical interventions. Longevity clinics increasingly integrate genomic testing, biomarker panels, imaging and AI-enabled digital coaching into subscription-based service models, creating structured pathways for preventive care.
In April 2025, longevity clinic networks such as Fountain Life and Next Health offered tiered membership programmes-ranging from entry-level assessments to premium plans incorporating advanced diagnostics and physician-supervised interventions-while platforms like Mahalo Health combined AI-driven health assessments with wearable data to support personalised monitoring. At the regulatory level, in 2024, the U.S. Food and Drug Administration announced it was exploring the use of artificial intelligence and machine learning to improve detection of Parkinson's disease symptoms using data from wearables and smartphones, reinforcing the clinical relevance of digital biomarkers in ageing populations.
Together, these developments highlight how digital health and clinic-based longevity services are creating recurring-revenue models, sustained patient engagement and outcome-aligned care delivery, strengthening the commercial and clinical foundations of the longevity market.
Regulatory and Cost Barriers Remain Key Constraints on Market Adoption
While interest in longevity solutions continues to grow, the market still faces practical challenges that affect how quickly these offerings can scale. In most regions, ageing itself is not recognised as a medical condition, which limits how therapies can be approved, marketed and reimbursed. As a result, companies often have to position longevity innovations through specific age-related diseases, adding complexity to development and slowing decision-making for investors and healthcare partners.
Affordability also remains an important consideration. Many longevity solutions rely on advanced testing, personalised assessments and ongoing clinical oversight, which increases costs and currently places these services out of reach for large parts of the population. In addition, building clinical evidence over long time horizons and investing in sophisticated technologies requires significant upfront funding, which can slow expansion beyond early-adopter groups. Greater regulatory clarity, wider payer participation and continued progress in reducing delivery costs will be essential to support broader access and unlock the full potential of the longevity market.
Key Questions Answered
- How is the longevity market evolving?
- What is driving and restraining the longevity market?
- How will each longevity submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
- How will the market shares for each longevity submarket develop from 2026 to 2036?
- What will be the main driver for the overall market from 2026 to 2036?
- Will leading longevity markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
- Who are the leading players and what are their prospects over the forecast period?
- What are the longevity projects for these leading companies?
- How will the industry evolve during the period between 2026 and 2036? What are the implications of longevity projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the longevity market?
- Where is the longevity market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Market Dynamics
Market Driving Factors
- Rapid Population Aging and Chronic Disease Burden
- Technological Advances in AI, Genomics and Regenerative Medicine
- Shift Toward Preventive and Personalized Healthspan Solutions
Market Restraining Factors
- Regulatory Uncertainty and Lack of Aging as a Disease Category
- High Costs and Funding/Investment Challenges
- Ethical, Social, and Data-Privacy Concerns
Market Opportunities
- AI-enabled Drug Discovery and Biomarker Discovery
- Personalized Wellness, Nutraceuticals and Functional Foods
- Digital Health, Remote Monitoring and Longevity Clinics
Leading Companies Profiled
- AbbVie Inc.
- Alkahest, Inc.
- Bristol-Myers Squibb Company
- CELLINK
- Elysium Health
- GSK plc
- Juvenescence Ltd.
- Insilico Medicine
- Life Biosciences, Inc.
- Rejuvenate Bio
- Serina Therapeutics, Inc.
Segments Covered in the Report
By Product & Services
Product
- Dietary Supplements
- Therapeutic Drugs and Biologics
- Anti-aging Skin Care Products
- Telehealth Solutions
- Medical Devices
- Health Monitoring Devices
Service
- Health and Wellness Services
- Fitness Programs
- Life Extension Therapies
- Genetic Testing
- Nutraceutical Services / Programs
By Intervention
Modern or Clinical Interventions
- Immunotherapy
- Gene Therapy
- Senolytic Drug Therapy
- Others
Traditional Alternative Medicine and Botanicals
- Traditional Chinese Medicine
- Ayurveda
- Naturopathic Medicine
- Others
Body Healing
- Yoga
- Acupuncture and Massage
- Chiropractic
- Qigong and Tai chi
- Kinesiology
- Reflexology
- Eurythmy
- Others
Mind Healing
- Meditation & Mindfulness
- Relaxation
- Others
External Energy Healing
- Magnetic and Electromagnetic Therapy
- Reiki
- Chakra Healing
- Others
Sensory Healing
- Aromatherapy
- Sound Healing
By Application
- Non-Clinical Applications
- Preventive Wellness
- Anti-aging and Skin Health
- Stress Management and Cognitive Enhancement
- General Longevity and Vitality
- Others
- Clinical Applications
- Cancer
- Cardiovascular Diseases
- Diabetes
- Others
By Distribution Channel
- Online Retail
- Pharmacies
- Health and Wellness Stores
- Direct Sales
- Hospitals / Clinical Settings
By End-users
- Individuals
- Healthcare Providers
- Fitness Centers
- Corporate Wellness Programs
- Research Institutions
For more information about this report visit https://www.researchandmarkets.com/r/ajnhum
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
